Northeast Pharmaceutical Group Co., Ltd.

SZSE:000597 Stock Report

Market Cap: CN¥5.9b

Northeast Pharmaceutical Group Past Earnings Performance

Past criteria checks 4/6

Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 32.7%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.8% per year. Northeast Pharmaceutical Group's return on equity is 7.6%, and it has net margins of 4.8%.

Key information

32.7%

Earnings growth rate

30.5%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate1.8%
Return on equity7.6%
Net Margin4.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05
Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Recent updates

It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

Aug 07
It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

May 25
These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05
Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Revenue & Expenses Breakdown

How Northeast Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:000597 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 247,9053802,076108
31 Mar 247,8293462,270101
31 Dec 238,2433582,57397
30 Sep 238,6434422,839146
30 Jun 238,8953733,031146
31 Mar 238,8103522,913152
01 Jan 238,8093502,789160
30 Sep 228,6092022,727106
30 Jun 228,5551512,752102
31 Mar 228,4781292,77693
31 Dec 218,145992,71183
30 Sep 218,003372,61362
30 Jun 217,671142,53061
31 Mar 217,465712,45869
31 Dec 207,384122,45374
30 Sep 207,659-12,75176
30 Jun 207,8331132,78474
31 Mar 208,026972,90173
31 Dec 198,2201743,01464
30 Sep 197,8982142,880137
30 Jun 197,8281982,823154
31 Mar 197,6222002,724148
31 Dec 187,4671952,581145
30 Sep 187,1021962,44373
30 Jun 186,6591962,21472
31 Mar 186,2041601,98762
31 Dec 175,6761191,74058
30 Sep 175,271981,47026
30 Jun 175,176601,4160
31 Mar 175,016391,3180
31 Dec 164,814241,2360
30 Sep 164,581-1561,2040
30 Jun 164,122-2951,2040
31 Mar 164,031-3581,2230
31 Dec 153,834-3841,1530
30 Sep 154,006-1941,0780
30 Jun 154,092-771,0090
31 Mar 154,223-81,0390
31 Dec 144,333871,0770
30 Sep 144,260-271,2240
30 Jun 144,199-561,2260
31 Mar 144,022-771,1780
31 Dec 133,871-1671,1300
30 Sep 133,791-1681,0860

Quality Earnings: 000597 has high quality earnings.

Growing Profit Margin: 000597's current net profit margins (4.8%) are higher than last year (4.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 000597's earnings have grown significantly by 32.7% per year over the past 5 years.

Accelerating Growth: 000597's earnings growth over the past year (2.1%) is below its 5-year average (32.7% per year).

Earnings vs Industry: 000597 earnings growth over the past year (2.1%) exceeded the Pharmaceuticals industry 0.4%.


Return on Equity

High ROE: 000597's Return on Equity (7.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies